Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Added 26/08/09: An open label, randomised, study to assess the efficacy and safety of Zenapax (daclizumab) or a single high dose of Anti-Thymocyte Globulin (ATG-Fresenius) for the prevention of acute rejection in patients receiving de novo simultaneous pancreas kidney transplantation treated with CellCept, Neoral and corticosteroids.

Next Previous
X
Search
Trial Profile

Added 26/08/09: An open label, randomised, study to assess the efficacy and safety of Zenapax (daclizumab) or a single high dose of Anti-Thymocyte Globulin (ATG-Fresenius) for the prevention of acute rejection in patients receiving de novo simultaneous pancreas kidney transplantation treated with CellCept, Neoral and corticosteroids.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2009

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Daclizumab (Primary) ; Ciclosporin; Mycophenolate mofetil; Prednisone
  • Indications Kidney-pancreas transplant rejection
  • Focus Therapeutic Use
  • Acronyms COMPAS

    • Most Recent Events

    • 06 Sep 2009 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top